TriSalus Life Sciences, Inc. $TLSI Stock Holdings Lifted by State Street Corp

Key Points

• State Street increased its TriSalus Life Sciences stake by 86.3% in the second quarter, bringing its holdings to 610,963 shares valued at approximately $2.78 million. Institutional investors and hedge funds collectively own 2.58% of the company.
• Analyst views remain mixed: three analysts rate TLSI a Buy, one rates it Hold and one rates it Sell. The stock has an average “Hold” rating and an average price target of $10.20.
• TriSalus reported a quarterly loss of $0.16 per share, in line with estimates, while revenue of $11.41 million exceeded expectations of $10.27 million. Shares opened at $4.34, with a 12-month range of $2.20 to $7.95.

State Street Corp lifted its stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 86.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 610,963 shares of the company's stock after purchasing an additional 282,943 shares during the quarter. State Street Corp owned about 0.99% of TriSalus Life Sciences worth $2,780,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Bank of America Corp DE raised its position in TriSalus Life Sciences by 1.9% during the 1st quarter. Bank of America Corp DE now owns 201,719 shares of the company's stock worth $807,000 after buying an additional 3,703 shares during the last quarter. Cura Wealth Advisors LLC acquired a new stake in TriSalus Life Sciences in the second quarter valued at about $36,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences in the 1st quarter valued at approximately $124,000. Deutsche Bank AG purchased a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $221,000. Finally, Corient Private Wealth LP boosted its holdings in TriSalus Life Sciences by 61.7% in the 2nd quarter. Corient Private Wealth LP now owns 147,152 shares of the company's stock valued at $670,000 after purchasing an additional 56,152 shares in the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TLSI. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. HC Wainwright upped their price objective on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Wednesday. Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 23rd. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday. Finally, Zacks Research upgraded shares of TriSalus Life Sciences to a "hold" rating in a research report on Thursday, September 10th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, TriSalus Life Sciences currently has an average rating of "Hold" and an average target price of $10.20.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.34 on Friday. The firm has a market capitalization of $267.26 million, a price-to-earnings ratio of -3.34 and a beta of 0.44. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. The business's 50 day simple moving average is $4.90 and its 200-day simple moving average is $4.32. TriSalus Life Sciences, Inc. has a 12 month low of $2.20 and a 12 month high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million. As a group, equities analysts forecast that TriSalus Life Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company's approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.